Company: SMNR
Filing Date: 2025-08-15
Form Type: 10-Q
Source: 0001213900-25-077047
Chunk: 205

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-15
Form: 10-Q
Item: Part II, Item 3
Chunk 205
---
III. SIGNATURES

Pursuant to the requirements of Securities Exchange
Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

    Date: August 15, 2025
    DENALI CAPITAL ACQUISITION CORP.

    By: 
    /s/ Lei Huang

    Chief Executive Officer

    (Principal Executive Officer)

    By:
    /s/ You “Patrick” Sun

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

39

NONE
NONE
NONE

http://fasb.org/srt/2025#ChiefExecutiveOfficerMember
0001913577
false
Q2
--12-31

    0001913577

    2025-01-01
    2025-06-30

    0001913577
    
      deca:UnitsEachConsistingOfOneClassAOrdinaryShareAndOneRedeemableWarrantMember

    2025-01-01
    2025-06-30

    0001913577
    
      deca:ClassAOrdinarySharesParValue00001PerShareMember

    2025-01-01
    2025-06-30

    0001913577
    
      deca:WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember

    2025-01-01
    2025-06-30

    0001913577
    
      us-gaap:CommonClassAMember

    2025-08-05

    0001913577
    
      us-gaap:CommonClassBMember

    2025-08-05

    0001913577

    2025-06-30

    0001913577

    2024-12-31

    0001913577
    
      us-gaap:RelatedPartyMember

    2025-06-30

    0001913577
    
      us-gaap:RelatedPartyMember

    2024-12-31

    0001913577
    
      us-gaap:CommonClassAMember

    2025-06-30

    0001913577
    
      us-gaap